tirzepatide half-life 5 days 116 hours How Long Stays in Your System (Half-Life Explained) The promise of tirzepatide: A
Description
Willard FS, Douros JD, Gabe MB, et al
There Are Better Options
Weight-loss drug approved to treat sleep apnea in Canada Sleep apnea causes daytime sleepiness and is often tied to obesity Health Canada has approved weight-loss drug Zepbound for treating obstructive sleep apnea in adults with obesity
Contact your healthcare provider to discuss symptoms and explore management strategies while continuing treatment
For those without insurance or paying out of pocket, Zepbound single-dose vials and Zepbound Kwikpen a multi-dose pen where a new needle is attached each week for four weeks may offer a more affordable option
